Pemafibrate: First Global Approval

被引：49

作者：

Blair, Hannah A. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2017年 / 77卷 / 16期

关键词：

PPAR-ALPHA MODULATOR; SPPARM-ALPHA; DYSLIPIDEMIC PATIENTS; DOUBLE-BLIND; K-877; HYPERLIPIDEMIA; POTENT;

D O I：

10.1007/s40265-017-0818-x

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Pemafibrate (Parmodia (R)) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-alpha modulator (SPPARM). It acts by binding to PPAR-alpha and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidaemia.

引用

页码：1805 / 1810

页数：6

共 15 条

[1]

[Anonymous], 2015, EUR HEART J S1

[2]

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia [J].

Arai, Hidenori ;

Yamashita, Shizuya ;

Yokote, Koutaro ;

Araki, Eiichi ;

Suganami, Hideki ;

Ishibashi, Shun .

ATHEROSCLEROSIS, 2017, 261 :144-152

[3]

Araki E, 2016, DIABETOLOGIA, V59, pS531

[4]

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis [J].

Hennuyer, Nathalie ;

Duplan, Isabelle ;

Paquet, Charlotte ;

Vanhoutte, Jonathan ;

Woitrain, Eloise ;

Touche, Veronique ;

Colin, Sophie ;

Vallez, Emmanuelle ;

Lestavel, Sophie ;

Lefebvre, Philippe ;

Staels, Bart .

ATHEROSCLEROSIS, 2016, 249 :200-208

[5]

ISHIBASHI S, 2013, CIRCULATION S, V128

[6]

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial [J].

Ishibashi, Shun ;

Yamashita, Shizuya ;

Arai, Hidenori ;

Araki, Eiichi ;

Yokote, Koutaro ;

Suganami, Hideki ;

Fruchart, Jean-Charles ;

Kodama, Tatsuhiko .

ATHEROSCLEROSIS, 2016, 249 :36-43

[7]

Kowa Co, 2017, PARMODIA TAB 0 1 MG

[8]

Kowa Co Ltd, 2017, TREAT HYP PARM TABL

[9]

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver [J].

Raza-Iqbal, Sana ;

Tanaka, Toshiya ;

Anai, Motonobu ;

Inagaki, Takeshi ;

Matsumura, Yoshihiro ;

Ikeda, Kaori ;

Taguchi, Akashi ;

Gonzalez, Frank J. ;

Sakai, Juro ;

Kodama, Tatsuhiko .

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (08) :754-772

[10]

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice [J].

Sairyo, Masami ;

Kobayashi, Takuya ;

Masuda, Daisaku ;

Kanno, Koutaro ;

Zhu, Yinghong ;

Okada, Takeshi ;

Koseki, Masahiro ;

Ohama, Tohru ;

Nishida, Makoto ;

Sakata, Yasushi ;

Yamashita, Shizuya .

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (02) :142-152

← 1 2 →